REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 8th, 2001 • Chiron Corp • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT is made and entered into as of June 12, 2001 by and between Chiron Corporation, a Delaware corporation ("the Company"), and Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated (the "Initial Purchaser"), pursuant to a purchase agreement, dated June 7, 2001 (the "Purchase Agreement"), between the Company and the Initial Purchaser. In order to induce the Initial Purchaser to enter into the Purchase Agreement, the Company has agreed to provide the registration rights set forth in this Agreement. The execution of this Agreement is a condition to the closing under the Purchase Agreement.
SECOND AMENDMENT AGREEMENTAgreement • August 8th, 2001 • Chiron Corp • Pharmaceutical preparations • California
This Second Amendment Agreement is made and dated as of June 15, 2001 between Schering Aktiengesellschaft ("Schering") and Chiron Corporation ("Chiron").
BLOOD SCREENING HCV PROBE LICENSE AGREEMENT between CHIRON CORPORATION and ROCHE MOLECULAR SYSTEMS, INC.Screening HCV Probe License Agreement • August 8th, 2001 • Chiron Corp • Pharmaceutical preparations
This agreement (hereinafter "Agreement") is made by and between CHIRON CORPORATION, a Delaware corporation, of 4560 Horton Street, Emeryville, California 94608 (hereinafter referred to as "CHIRON"), F. HOFFMANN-LA ROCHE LTD., a Swiss corporation, of Grenzacherstrasse 124, Basel, Switzerland (hereinafter referred to as "ROCHE PARENT"), and ROCHE MOLECULAR SYSTEMS, INC., a Delaware corporation, of 1145 Atlantic Avenue, Suite 100, Alameda, California 94501 (hereinafter referred to as "RMS" and collectively with ROCHE PARENT, "ROCHE").
BLOOD SCREENING HIV PROBE LICENSE AGREEMENT between CHIRON CORPORATION F. HOFFMANN-LA ROCHE LTD. and ROCHE MOLECULAR SYSTEMS, INC.Probe License Agreement • August 8th, 2001 • Chiron Corp • Pharmaceutical preparations
This agreement (hereinafter "Agreement") is made by and between CHIRON CORPORATION, a Delaware corporation, of 4560 Horton Street, Emeryville, California 94608 (hereinafter referred to as "CHIRON"), F. HOFFMANN-LA ROCHE LTD., a Swiss corporation, of Grenzacherstrasse 124, Basel, Switzerland (hereinafter referred to as "ROCHE PARENT"), and ROCHE MOLECULAR SYSTEMS, INC., a Delaware corporation, of 1145 Atlantic Avenue, Suite 100, Alameda, California 94501 (hereinafter referred to as "RMS" and collectively with ROCHE PARENT, "ROCHE").
